Exchange: OTC·Updated 09:40 AM EST

MDXXF News

News
all
press releases
Momentum continues to build across the emerging psychedelic medicine sector as PharmAla Biotech (OTCQB:MDXXF) announced a definitive licensing agreement granting Jupiter Neurosciences (NASDAQ:JUNS) exclusive rights to develop, manufacture, and commercialize ALA-002 in the United States. The agreement, valued at up to approximately US$100 million in potential consideration, reflects the growing interest in next-generation neuropsychiatric therapies and strategic partnerships designed to advance promising clinical assets while managing development risk.
24-7 Market News
The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...
AllPennyStocks.com
The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...
AllPennyStocks.com

Advertisement|Remove ads.